Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
135 shown of 2,377 total abstracts
  1. Abstract 17382026-09-03 · 21:15 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-248
    G. Curigliano, J. Brahmer, E. Winer, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 17782026-09-01 · 18:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-50 study)
    P. Schmid, S. Peters, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 95842026-09-01 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-524
    T. Mok, E. Winer, P. Schmid, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 18082026-09-04 · 21:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-118
    S. Peters, R. Herbst, C. Saura, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 43182026-09-01 · 21:15 CT · Hall B1
    EV-316: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    J. Cortes, S. Antonia · Dana-Farber Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 52352026-09-03 · 15:15 CT · S100A
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-755
    P. Schmid, N. Rizvi, A. Spira · Dana-Farber Cancer Institute
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  7. Abstract 94872026-09-04 · 18:15 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    S. Peters, C. Robert, M. Reck, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 99122026-09-03 · 18:15 CT · E450
    PACIFIC-50: Imfinzi (durvalumab) 1L in SCLC
    C. Saura, M.C. Garassino, A. Spira, et al. · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Small Cell📄🖼️
  9. Abstract 13372026-09-05 · 15:45 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-494
    C. Robert, F. Andre · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 18902026-09-03 · 13:30 CT · E450
    MONALEESA-160: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    C. Saura, A. Spira, H. Borghaei · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 14562026-09-04 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    G. Curigliano, R. Herbst · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 96382026-09-01 · 13:45 CT · S100A
    CheckMate-838: Opdivo (nivolumab) adjuvant in metastatic melanoma
    C. Saura, H. Rugo, J. Cortes, et al. · MD Anderson Cancer Center
    Education SessionMelanoma📄🖼️
  13. Abstract 11682026-09-03 · 20:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-473
    G. Curigliano, P. Schmid, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 46632026-09-01 · 20:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    M. Reck, S. Peters, L. Paz-Ares · Peter MacCallum Cancer Centre
    Education SessionGastrointestinal Cancer📄🖼️
  15. Abstract 11952026-09-02 · 18:45 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    M. Reck, E. Winer · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 91472026-09-01 · 13:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-484 study)
    M.C. Garassino, S. Modi, C. Saura · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 17212026-09-03 · 18:15 CT · Hall B1
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-782
    M.C. Garassino, C. Robert, M. Krop, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 91922026-09-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-539 study)
    L. Paz-Ares, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  19. Abstract 16892026-09-01 · 21:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-513 study)
    C. Robert, E. Winer · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 15812026-09-02 · 18:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-283
    M. Krop, E. Winer, S. Tolaney, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 13652026-09-02 · 20:30 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-710
    M. Krop, M.C. Garassino, N. Rizvi, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 44742026-09-05 · 15:00 CT · S406
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-69
    S. Tolaney, P. Schmid, C. Robert · Massachusetts General Hospital
    Education SessionGastrointestinal Cancer📄🖼️
  23. Abstract 41612026-09-02 · 13:00 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with HCC
    A. Spira, T. Mok, J. Cortes, et al. · Princess Margaret Cancer Centre
    Education SessionGastrointestinal Cancer📄🖼️
  24. Abstract 93172026-09-03 · 20:30 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    C. Robert, N. Rizvi · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Small Cell📄🖼️
  25. Abstract 97982026-09-05 · 18:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-728 study)
    S. Antonia, S. Modi · Stanford Cancer Institute
    Education SessionMelanoma📄🖼️
  26. Abstract 45342026-09-05 · 21:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with gastric
    S. Peters, F. Andre · Mayo Clinic
    Education SessionGastrointestinal Cancer📄🖼️
  27. Abstract 16522026-09-01 · 15:30 CT · S100A
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-878
    C. Robert, S. Peters, A. Spira · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 17382026-09-05 · 15:15 CT · E450
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-505
    S. Antonia, S. Tolaney, L. Paz-Ares, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 42502026-09-03 · 20:00 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in HCC
    J. Cortes, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  30. Abstract 17482026-09-02 · 18:00 CT · E450
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-234
    N. Rizvi, J. Brahmer, C. Saura, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 98482026-09-03 · 16:30 CT · Arie Crown Theater
    PACIFIC-165: Imfinzi (durvalumab) 1L in SCLC
    J. Brahmer, G. Curigliano, R. Herbst · Chinese University of Hong Kong
    Education SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 90072026-09-05 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-388
    A. Spira, H. Rugo, M. Krop · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 68712026-09-02 · 19:45 CT · S406
    CheckMate-450: Opdivo (nivolumab) maintenance in RCC
    S. Tolaney, M. Krop, M.C. Garassino, et al. · Massachusetts General Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 10492026-09-02 · 13:00 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    T. Mok, C. Saura · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 45942026-09-01 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    S. Modi, S. Tolaney, E. Winer · Institut Gustave Roussy
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 19772026-09-01 · 14:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-296
    M. Krop, J. Cortes, C. Saura, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 42552026-09-04 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-108 study)
    M. Krop, M. Reck · Memorial Sloan Kettering Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  38. Abstract 16552026-09-03 · 16:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-738
    H. Borghaei, F. Andre, S. Peters, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 45732026-09-03 · 19:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-738 study)
    S. Peters, M. Krop, G. Curigliano, et al. · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 94492026-09-02 · 19:45 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-67
    M. Reck, R. Herbst, A. Spira, et al. · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 13032026-09-03 · 21:45 CT · S406
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-229
    P. Schmid, S. Peters, S. Tolaney, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 14922026-09-02 · 19:30 CT · E450
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-273
    C. Robert, P. Schmid, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 57682026-09-04 · 13:45 CT · Hall B1
    OlympiA-679: Lynparza (olaparib) maintenance in prostate
    J. Cortes, C. Robert, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  44. Abstract 13832026-09-01 · 19:15 CT · Arie Crown Theater
    MONALEESA-533: Kisqali (ribociclib) 2L in HR+ breast cancer
    S. Modi, H. Rugo, F. Andre, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 91752026-09-03 · 18:15 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with NSCLC
    R. Herbst, M.C. Garassino, L. Paz-Ares · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 44782026-09-03 · 21:15 CT · Arie Crown Theater
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    C. Robert, J. Cortes, S. Antonia, et al. · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 92382026-09-03 · 19:30 CT · S100A
    Quality of life outcomes with Tecentriq in patients with NSCLC
    J. Cortes, C. Saura, P. Schmid · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 13112026-09-05 · 15:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-703
    M.C. Garassino, S. Modi · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 94332026-09-04 · 14:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-567 study)
    M.C. Garassino, J. Cortes, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 16222026-09-01 · 19:45 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-525
    P. Schmid, M.C. Garassino, H. Borghaei, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 95922026-09-03 · 18:00 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    C. Saura, T. Mok, F. Andre · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 53482026-09-02 · 13:45 CT · E450
    OlympiA-368: Lynparza (olaparib) 3L+ in prostate
    M. Krop, F. Andre, M. Reck · Mayo Clinic
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  53. Abstract 56312026-09-05 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-674 study)
    C. Robert, F. Andre · University of Chicago
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  54. Abstract 16962026-09-02 · 13:00 CT · Arie Crown Theater
    ASCENT-215: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    L. Paz-Ares, S. Tolaney, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 19042026-09-02 · 14:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-74
    A. Spira, N. Rizvi, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 99182026-09-02 · 21:15 CT · E450
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-626
    P. Schmid, R. Herbst · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 12522026-09-01 · 13:15 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    T. Mok, H. Rugo, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 19762026-09-05 · 20:15 CT · E450
    MONALEESA-208: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    S. Antonia, R. Herbst, P. Schmid, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 41642026-09-04 · 19:00 CT · Arie Crown Theater
    ASCENT-937: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    J. Brahmer, J. Cortes, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract 95642026-09-03 · 13:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-111
    S. Tolaney, S. Antonia, H. Borghaei · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 62892026-09-05 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with ovarian
    J. Cortes, S. Modi, M. Reck · Cleveland Clinic
    Education SessionGynecologic Cancer📄🖼️
  62. Abstract 19452026-09-01 · 14:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-406 study)
    F. Andre, G. Curigliano, R. Herbst, et al. · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 99822026-09-03 · 19:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-646 study)
    E. Winer, G. Curigliano · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 101682026-09-02 · 19:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-2 study)
    M. Reck, S. Peters, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Education SessionMelanoma📄🖼️
  65. Abstract 55192026-09-04 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with prostate
    E. Winer, J. Brahmer · University of Chicago
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  66. Abstract 60072026-09-02 · 20:30 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in RCC
    J. Brahmer, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  67. Abstract 94262026-09-01 · 16:15 CT · E450
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-533
    S. Peters, G. Curigliano · National Cancer Center Japan
    Education SessionLung Cancer—Small Cell📄🖼️
  68. Abstract 11592026-09-05 · 13:30 CT · Hall B1
    MONARCH-456: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, M. Reck, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 49652026-09-05 · 18:45 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-377 study)
    J. Brahmer, H. Borghaei, C. Saura, et al. · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  70. Abstract 46802026-09-05 · 13:15 CT · S100A
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-928 study)
    J. Cortes, C. Saura · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  71. Abstract 19982026-09-03 · 15:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-155
    L. Paz-Ares, C. Robert · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 98982026-09-04 · 19:45 CT · S406
    Quality of life outcomes with Tagrisso in patients with NSCLC
    N. Rizvi, M. Reck · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 97332026-09-04 · 15:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-254
    T. Mok, J. Cortes, M. Reck · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 19072026-09-04 · 20:30 CT · S406
    MONALEESA-949: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    J. Cortes, N. Rizvi, M. Krop, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 64152026-09-02 · 13:15 CT · Hall B1
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-818
    T. Mok, A. Spira, S. Peters, et al. · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  76. Abstract 103572026-09-02 · 21:15 CT · S406
    KEYNOTE-699: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    C. Robert, R. Herbst, M. Krop, et al. · Mayo Clinic
    Education SessionMelanoma📄🖼️
  77. Abstract 61522026-09-02 · 13:00 CT · E450
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-763
    J. Brahmer, S. Peters, M.C. Garassino, et al. · Royal Marsden Hospital
    Education SessionGynecologic Cancer📄🖼️
  78. Abstract 93332026-09-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-22
    P. Schmid, C. Saura, S. Antonia, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 48982026-09-02 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu neoadjuvant for gastric: DESTINY-Breast-390
    M. Reck, S. Antonia, A. Spira · National Cancer Center Japan
    Education SessionGastrointestinal Cancer📄🖼️
  80. Abstract 12182026-09-03 · 14:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-272 study)
    A. Spira, C. Saura, G. Curigliano, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 17122026-09-05 · 15:30 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    J. Cortes, M.C. Garassino, S. Antonia, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 14732026-09-02 · 21:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-929 study)
    L. Paz-Ares, A. Spira, F. Andre, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 104242026-09-02 · 21:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-92
    L. Paz-Ares, M. Reck, S. Modi, et al. · Stanford Cancer Institute
    Education SessionMelanoma📄🖼️
  84. Abstract 19372026-09-02 · 19:30 CT · S406
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-517
    S. Antonia, R. Herbst, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 19552026-09-04 · 16:30 CT · E450
    MONARCH-952: Verzenio (abemaciclib) 1L in HR+ breast cancer
    F. Andre, L. Paz-Ares · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 92212026-09-05 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-749 study)
    T. Mok, F. Andre, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 46082026-09-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-334 study)
    F. Andre, A. Spira, M.C. Garassino · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  88. Abstract 19492026-09-05 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-927
    T. Mok, H. Borghaei, J. Cortes, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 13202026-09-05 · 21:45 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    R. Herbst, A. Spira · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 96282026-09-05 · 20:00 CT · E450
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-937
    P. Schmid, M. Krop, H. Borghaei, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 91542026-09-01 · 16:30 CT · S406
    Quality of life outcomes with Keytruda in patients with SCLC
    J. Brahmer, M. Krop, P. Schmid, et al. · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Small Cell📄🖼️
  92. Abstract 94702026-09-02 · 20:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    J. Cortes, P. Schmid, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  93. Abstract 47572026-09-05 · 20:30 CT · S406
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-656
    S. Peters, M. Krop, H. Borghaei, et al. · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  94. Abstract 98462026-09-01 · 19:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-721 study)
    A. Spira, S. Modi · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 11472026-09-02 · 15:15 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    T. Mok, C. Saura, M. Krop · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 41852026-09-05 · 14:45 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-422
    J. Cortes, A. Spira, R. Herbst, et al. · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  97. Abstract 19632026-09-05 · 18:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-40 study)
    H. Rugo, T. Mok, S. Antonia, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 46052026-09-03 · 19:00 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    M.C. Garassino, R. Herbst, P. Schmid · Mayo Clinic
    Education SessionGastrointestinal Cancer📄🖼️
  99. Abstract 47222026-09-05 · 16:45 CT · E450
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-116
    H. Borghaei, A. Spira · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  100. Abstract 93992026-09-01 · 21:00 CT · S406
    CheckMate-230: Opdivo (nivolumab) maintenance in NSCLC
    C. Saura, S. Modi, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 19492026-09-04 · 18:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-397
    E. Winer, S. Modi · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 17212026-09-03 · 19:45 CT · E450
    ASCENT-944: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    S. Modi, G. Curigliano, C. Saura · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 99072026-09-01 · 13:30 CT · S100A
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-176
    M. Krop, L. Paz-Ares, S. Antonia, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 93792026-09-05 · 15:15 CT · Arie Crown Theater
    DESTINY-Breast-974: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    F. Andre, J. Brahmer · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 15552026-09-02 · 13:15 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-337
    L. Paz-Ares, J. Cortes, A. Spira, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 16862026-09-04 · 13:30 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-905
    S. Peters, M. Krop · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 48892026-09-03 · 18:30 CT · Arie Crown Theater
    ASCENT-667: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    F. Andre, R. Herbst, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 15352026-09-05 · 15:15 CT · E450
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-604
    R. Herbst, S. Antonia, S. Tolaney · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 13742026-09-01 · 16:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-464 study)
    J. Cortes, A. Spira, R. Herbst · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 15922026-09-02 · 16:45 CT · Arie Crown Theater
    ASCENT-158: Trodelvy (sacituzumab govitecan) 2L in TNBC
    M. Krop, H. Rugo, M. Reck · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 10672026-09-04 · 19:45 CT · Arie Crown Theater
    OlympiA-733: Lynparza (olaparib) 3L+ in HR+ breast cancer
    S. Peters, L. Paz-Ares, J. Brahmer · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 14952026-09-03 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-319
    L. Paz-Ares, N. Rizvi · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 18292026-09-02 · 20:15 CT · Hall B1
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-741
    F. Andre, G. Curigliano, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 91522026-09-04 · 13:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-25
    N. Rizvi, P. Schmid, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 14312026-09-04 · 20:30 CT · Arie Crown Theater
    MONALEESA-398: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    M.C. Garassino, A. Spira, M. Krop, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 43582026-09-04 · 16:30 CT · S100A
    EV-551: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    M. Reck, M. Krop, S. Antonia, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  117. Abstract 63742026-09-02 · 16:30 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-205 study)
    M. Reck, A. Spira, F. Andre, et al. · Cleveland Clinic
    Education SessionGynecologic Cancer📄🖼️
  118. Abstract 91262026-09-03 · 13:45 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-32
    F. Andre, P. Schmid, C. Robert, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 16612026-09-03 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-919 study)
    J. Brahmer, E. Winer · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 16222026-09-03 · 14:00 CT · E450
    MONARCH-585: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    R. Herbst, S. Tolaney, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 99612026-09-01 · 16:00 CT · Hall B1
    PACIFIC-88: Imfinzi (durvalumab) 2L in SCLC
    P. Schmid, C. Saura · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Small Cell📄🖼️
  122. Abstract 90862026-09-02 · 16:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-339
    J. Cortes, C. Robert, J. Brahmer · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  123. Abstract 61652026-09-01 · 21:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-480
    C. Robert, S. Modi, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionGynecologic Cancer📄🖼️
  124. Abstract 15632026-09-01 · 19:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-488 study)
    J. Cortes, A. Spira, M. Krop · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 16402026-09-04 · 15:45 CT · S100A
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-353
    S. Tolaney, S. Peters, T. Mok · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 15782026-09-04 · 19:15 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-187
    L. Paz-Ares, M.C. Garassino, J. Cortes · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 56452026-09-05 · 20:00 CT · S100A
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-120 study)
    A. Spira, R. Herbst, P. Schmid · Karolinska Institute
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  128. Abstract 94152026-09-01 · 16:00 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-709 study)
    S. Peters, A. Spira, J. Cortes · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Small Cell📄🖼️
  129. Abstract 47882026-09-03 · 14:45 CT · Arie Crown Theater
    CheckMate-740: Opdivo (nivolumab) 1L in HCC
    C. Robert, E. Winer, M. Reck, et al. · Chinese University of Hong Kong
    Education SessionGastrointestinal Cancer📄🖼️
  130. Abstract 95592026-09-01 · 15:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-245 study)
    M. Reck, J. Brahmer, A. Spira, et al. · Dana-Farber Cancer Institute
    Education SessionMelanoma📄🖼️
  131. Abstract 43312026-09-02 · 19:15 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-420
    S. Modi, E. Winer, S. Peters, et al. · Mayo Clinic
    Education SessionGastrointestinal Cancer📄🖼️
  132. Abstract 97572026-09-02 · 18:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-854 study)
    P. Schmid, R. Herbst, M.C. Garassino, et al. · National Cancer Center Japan
    Education SessionMelanoma📄🖼️
  133. Abstract 91962026-09-03 · 16:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    E. Winer, J. Cortes, M. Reck, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 95602026-09-02 · 21:45 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    C. Robert, M. Krop, M.C. Garassino · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 60472026-09-03 · 18:15 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-202
    C. Robert, F. Andre, J. Cortes · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.